Literature DB >> 18630995

Expanding indications for recombinant human TSH in thyroid cancer.

Bryan R Haugen, David S Cooper, Charles H Emerson, Markus Luster, Rui M B Maciel, Rosa P M Biscolla, Ernest L Mazzaferri, Geraldo Medeiros-Neto, Christoph Reiners, Richard J Robbins, Bruce G Robinson, Martin Schlumberger, Shunichi Yamashita, Furio Pacini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18630995      PMCID： PMC2637556          DOI： 10.1089/thy.2008.0162

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  34 in total

1.  Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm?

Authors:  Pedro W S Rosário; Michelle A R Borges; Maristane M A Valadão; Flávio P J Vasconcelos; Leonardo L Rezende; Eduardo L Padrão; Alvaro L Barroso; Saulo Purisch
Journal:  Thyroid       Date:  2007-12       Impact factor: 6.568

Review 2.  Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when.

Authors:  D Barbaro; G Boni
Journal:  Eur J Surg Oncol       Date:  2007-03-06       Impact factor: 4.424

3.  Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine.

Authors:  Richard J Robbins; Albert Driedger; James Magner
Journal:  Thyroid       Date:  2006-11       Impact factor: 6.568

Review 4.  How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.

Authors:  Martin Schlumberger; Marcel Ricard; Gérard De Pouvourville; Furio Pacini
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-09

5.  [Thyroid nodules and differentiated thyroid cancer: Brazilian consensus].

Authors:  Ana Luiza Maia; Laura S Ward; Gisah A Carvalho; Hans Graf; Rui M B Maciel; Léa M Zanini Maciel; Pedro W Rosário; Mario Vaisman
Journal:  Arq Bras Endocrinol Metabol       Date:  2007-07

6.  Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.

Authors:  M G Castagna; L Brilli; T Pilli; A Montanaro; C Cipri; C Fioravanti; F Sestini; M Capezzone; F Pacini
Journal:  J Clin Endocrinol Metab       Date:  2007-10-30       Impact factor: 5.958

Review 7.  Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.

Authors:  P Zanotti-Fregonara; M E Toubert; D Taieb; L Ravasi; D Rubello; E Hindie
Journal:  Minerva Endocrinol       Date:  2008-03-11       Impact factor: 2.184

8.  Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal.

Authors:  I Borget; C Corone; M Nocaudie; M Allyn; S Iacobelli; M Schlumberger; G De Pouvourville
Journal:  Eur J Endocrinol       Date:  2007-05       Impact factor: 6.664

9.  Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.

Authors:  M Schlumberger; A Hitzel; M E Toubert; C Corone; F Troalen; M H Schlageter; F Claustrat; S Koscielny; D Taieb; M Toubeau; F Bonichon; F Borson-Chazot; L Leenhardt; C Schvartz; C Dejax; I Brenot-Rossi; M Torlontano; F Tenenbaum; S Bardet; F Bussière; J J Girard; O Morel; O Schneegans; J L Schlienger; A Prost; D So; F Archambeaud; M Ricard; E Benhamou
Journal:  J Clin Endocrinol Metab       Date:  2007-04-10       Impact factor: 5.958

10.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.

Authors:  Tania Pilli; Ernesto Brianzoni; Francesca Capoccetti; Maria Grazia Castagna; Sara Fattori; Angela Poggiu; Gloria Rossi; Francesca Ferretti; Elisa Guarino; Luca Burroni; Angelo Vattimo; Claudia Cipri; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2007-07-03       Impact factor: 5.958
View more
  6 in total

1.  What role for recombinant human TSH in the treatment of metastatic thyroid cancer?

Authors:  Paolo Zanotti-Fregonara; Elif Hindié; Marie Elisabeth Toubert; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06       Impact factor: 9.236

2.  Recombinant human thyrotropin use resulting in ovarian hyperstimulation: an unusual side effect.

Authors:  Tanvir Rizvi; Patrice K Rehm
Journal:  Eur Thyroid J       Date:  2014-06-07

3.  Evaluation of whole-body retention of iodine-131 ((131)I) after postoperative remnant ablation for differentiated thyroid carcinoma - thyroxine withdrawal versus rhTSH administration: A retrospective comparison.

Authors:  Maria Raquel Carvalho; Teresa C Ferreira; Valeriano Leite
Journal:  Oncol Lett       Date:  2011-12-14       Impact factor: 2.967

4.  Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for 131I Administration.

Authors:  Cristiane J Gomes-Lima; Sanjita Chittimoju; Leen Wehbeh; Sunita Dia; Prathyusha Pagadala; Mohammad Al-Jundi; Sakshi Jhawar; Eshetu Tefera; Mihriye Mete; Joanna Klubo-Gwiezdzinska; Douglas Van Nostrand; Jacqueline Jonklaas; Leonard Wartofsky; Kenneth D Burman
Journal:  J Endocr Soc       Date:  2022-03-02

5.  Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer.

Authors:  Bernadette Biondi; Melania Pulcrano; Loredana Pagano; Gaetano Lombardi
Journal:  Biologics       Date:  2009-07-13

6.  Effects of recombinant human thyrotropin administration on 24-hour arterial pressure in female undergoing evaluation for differentiated thyroid cancer.

Authors:  Gianna Rentziou; Katerina Saltiki; Efstathios Manios; Kimon Stamatelopoulos; Eleni Koroboki; Anastasia Vemmou; Emily Mantzou; Nikolaos Zakopoulos; Maria Alevizaki
Journal:  Int J Endocrinol       Date:  2014-08-18       Impact factor: 3.257
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.